SNPMiner Trials (Home Page)
Report for Clinical Trial NCT04042558
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
The objective of this study is to assess the efficacy of the combination of Platinum
(carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage
IIIB/IV non-squamous non-small cell lung cancer patients with progression-enhancing mutations
following targeted therapies.
NCT04042558 NSCLC Stage IIIB NSCLC Stage IV EGFR Gene Mutation ALK Gene Rearrangement Positive ROS1 Gene Mutation
2 Interventions
Name: Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
Description: 4 cycles of induction every 3 weeks of cisplatine,pemetrexed, atezolizumab + bevacizumab and patients without disease progression, treatment will be followed by maintenance therapy by Atezolizumab + Pemetrexed +/- Bevacizumab administered at the same dosage on 3-week cycles
Type: Drug
Group Labels: 1 Cohort with Bevacizumab
Name: Carboplatin + Pemetrexed + Atezolizumab
Description: Carboplatin + Pemetrexed + Atezolizumab
Type: Drug
Group Labels: 1 Cohort without Bevacizumab
Primary Outcomes
Measure: Objective response rate (ORR) according to RECIST 1.1 Time: After the end of 4 cycles (15 weeks)
Secondary Outcomes
Measure: The progression-free survival (PFS) Time: 1 year
Measure: The overall survival Time: 1 year
Measure: The duration of response Time: 1 year
Purpose: Treatment
Allocation: Non-Randomized
Parallel Assignment
There is one SNP
SNPs
After a first line of treatment with a TKI, most
patients progress and are eligible according to the mechanism of progression to a TKI of 3rd
generation in case of T790M resistance or chemotherapy. --- T790M ---
HPO Nodes